Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
By Ching‐lung Lai, D. Shouval, A. Lok, Ting Chang, H. Cheinquer, Z. Goodman, D. Dehertogh, R. Wilber, R. Zink, A. Cross and 2 more. New England Journal of Medicine, 2006
1,204 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/a7a9207cb6acba6a469d8393040f5e66444d7e92
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008, background): “Pivotal phase III randomized lamivudine controlled trials showed that 1-year entecavir (0.5 mg/day) is superior to lamivudine in reducing HBV-DNA in both HBeAg-positive (-6.9 log vs. -5.4 log; P \ 0.0001; HBV-DNA \ 300 copies/ml in 67% vs. 36%) [86] and HBeAg-negative patients (-5.0 log vs. -4.5 log”
- Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “TAF joins the list of preferred HBV therapies, along with entecavir, tenofovir disoproxil fumarate (TDF), and peginterferon (peg-IFN; Tables 1 and 2)((6-16)) (section: Updated Recommendations on the Treatment of Patients With Chronic Hepatitis B).”
- Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B (2010, result): “Complete inclusion criteria for enrollment in the ETV-022 (HBeAg-positive) and ETV-027 (HBeAg-negative) studies have been described previously.(21,22) Some key inclusion criteria were as follows: age 16 years; serological diagnosis of CHB; compensated liver function; absence of coinfection with hepa”
- EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “Entecavir and tenofovir are potent HBV inhibitors with a high barrier to resistance [67,70,78,85,92,123] (Fig.”